https://scholars.lib.ntu.edu.tw/handle/123456789/604454
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.author | Krop, Ian E | en_US |
dc.contributor.author | Im, Seock-Ah | en_US |
dc.contributor.author | Barrios, Carlos | en_US |
dc.contributor.author | Bonnefoi, Hervé | en_US |
dc.contributor.author | Gralow, Julie | en_US |
dc.contributor.author | Toi, Masakazu | en_US |
dc.contributor.author | Ellis, Paul A | en_US |
dc.contributor.author | Gianni, Luca | en_US |
dc.contributor.author | Swain, Sandra M | en_US |
dc.contributor.author | Im, Young-Hyuck | en_US |
dc.contributor.author | De Laurentiis, Michelino | en_US |
dc.contributor.author | Nowecki, Zbigniew | en_US |
dc.contributor.author | CHIUN-SHENG HUANG | en_US |
dc.contributor.author | Fehrenbacher, Louis | en_US |
dc.contributor.author | Ito, Yoshinori | en_US |
dc.contributor.author | Shah, Jigna | en_US |
dc.contributor.author | Boulet, Thomas | en_US |
dc.contributor.author | Liu, Haiying | en_US |
dc.contributor.author | Macharia, Harrison | en_US |
dc.contributor.author | Trask, Peter | en_US |
dc.contributor.author | Song, Chunyan | en_US |
dc.contributor.author | Winer, Eric P | en_US |
dc.contributor.author | Harbeck, Nadia | en_US |
dc.date.accessioned | 2022-04-15T02:33:29Z | - |
dc.date.available | 2022-04-15T02:33:29Z | - |
dc.date.issued | 2022 | - |
dc.identifier.issn | 0732183X | - |
dc.identifier.uri | https://scholars.lib.ntu.edu.tw/handle/123456789/604454 | - |
dc.description.abstract | We aimed to improve efficacy and reduce toxicity of high-risk human epidermal growth factor receptor 2 (HER2)-positive early breast cancer (EBC) treatment by replacing taxanes and trastuzumab with trastuzumab emtansine (T-DM1). | en_US |
dc.language.iso | en | en_US |
dc.relation.ispartof | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | en_US |
dc.subject.classification | [SDGs]SDG3 | - |
dc.title | Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: The Phase III KAITLIN Study | en_US |
dc.type | journal article | en |
dc.identifier.doi | 10.1200/JCO.21.00896 | - |
dc.identifier.pmid | 34890214 | - |
dc.identifier.scopus | 2-s2.0-85124438534 | - |
dc.identifier.url | https://api.elsevier.com/content/abstract/scopus_id/85124438534 | - |
dc.relation.journalvolume | 40 | en_US |
dc.relation.journalissue | 5 | en_US |
dc.relation.pageend | 448 | en_US |
item.languageiso639-1 | en | - |
item.cerifentitytype | Publications | - |
item.fulltext | no fulltext | - |
item.openairecristype | http://purl.org/coar/resource_type/c_6501 | - |
item.openairetype | journal article | - |
item.grantfulltext | none | - |
crisitem.author.dept | Surgery-NTUH | - |
crisitem.author.dept | Surgery | - |
crisitem.author.orcid | 0000-0002-6557-211X | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。